Current Pagliuca Life Lab Ventures
These biotech and life science ventures are current residents at the Pagliuca Harvard Life Lab.
-
Absco Therapeutics
AbscoTx injects image-guided therapy into tumors to educate the immune system to fight cancer locally and at metastatic sites.
-
Aperture Bio
Realizing orders-of-magnitude improvements in speed and sensitivity, Aperture rapidly analyzes proteins in whole cells to map immune interactions.
-
Boston Interactome
Reprogramming neuronal gene expression to treat brain disease.
-
Bullseye Biosciences
By leveraging competition and evolution, Bullseye aims to transform therapeutics discovery and expedite the development of life-saving medicines.
-
Core Biomedicine
Advancing cancer lineage therapeutics beyond genomics, with a focus on targeting cancer-specific core lineage-dependent pathways.
-
Illumicell AI
Providing AI-based sperm testing for healthcare providers, enabling accurate at-home fertility assessments for patients.
-
InGel Therapeutics
Regenerative cell-therapy biotech aiming to treat people affected by blindness.
-
Lightning Biotherapeutics
Sparking immune regeneration by harnessing the body’s inherent regenerative capacity to create novel therapeutics.
-
Linton Lifesciences
Using 3D bioprinting to create custom arteries for bypass surgery, aiming to replace traditional autologous grafts.
-
NuCyRNA Therapeutics
Redefining RNA-targeting therapeutics, starting in neurodegenerative diseases.
-
PathCision Medicine
Developing tissue-informed precision therapeutics with superior delivery and efficacy for cancer and other complex diseases.
-
Promakhos Therapeutics Inc.
Developing oral, non-immunosuppressive, small molecules to cure chronic inflammatory disorders.
-
Raptor Medicines
Raptor's next-gen aptamers enable targeted oligo delivery with antibody-like specificity, scalable manufacturing, and rapid development time.
-
Stratagen Bio
Transforming MRI scans into a tool for objective clinical decision-making and quantitative biomarker assessment.